abstract |
A dendrimer formation, such as a PAMAM dendrimer or a multiarm PEG polymeric formulation has been developed for systemic administration to the brain or central nervous system. In the preferred embodiment, the dendrimers are in the form of dendrimer nanoparticles comprising poly(amidoamine) (PAMAM) hydroxyl-terminated dendrimers covalently linked to at least one therapeutic, prophylactic or diagnostic agent for treatment of one or more symptoms of neurodegenerative, neurodevelopmental or neurological disorders such as Rett syndrome or autism spectrum disorders, D6 generation dendrimers provide significantly enhanced uptake into areas of brain Injury, providing a means for diagnosis as well, as drug delivery. |